Since Eliquis (BMS) won the final lawsuit against its substance patent, there has been a change in the direct oral anticoagulant (DOAC) market.
Eliquis rose to second place by overtaking Xarelto (Bayer), and its prescription sales increased significantly as generic drugs, which had been growing the sales, left the market.
The prescription sales amount of Eliquis in June was about 4.9 billion won, up 600 million won from a year earlier, according to the UBIST.
On the other hand, Xarelto’s prescription sales fell by one billion won to 3.3 billion won from 4.3 billion won over the same period, behind Eliquis by 1.5 billion won.
Lixiana (Daiichi Sankyo) maintained its lead by increasing its sales by 200 million won to 5.8 billion won, while Pradaxa (Boehringer Ingelheim) kept its 1 billion won mark with 1.1 billion won.
Generic drugs, which had been entering the 100 million won mark one after another, saw a significant decrease to less than 50 million won in prescription sales after losing the case.
Eliquis also outpaced Xarelto by about 500 million won in semiannual cumulative prescription sales as Xarelto lost 1.5 billion won in prescription sales from the same period last year, while Eliquis fell about 700 million won.
Lixiana was the only DOAC to have 30 billion won sales and to expand prescription sales YoY among four original drugs.
Pradaxa’s prescription sales decreased from 7.4 billion won to 6.3 billion won, while Liquisia (Chong Kun Dang Pharmaceutical) was the only generic product to exceed 1 billion won.
